Under the Medicare Part D outpatient prescription drug benefit program, Part D plans are required to cover a minimum of two drugs in each therapeutic category and class, but from the outset, Medicare has been prohibited by law from covering medications when used specifically for weight loss
IL-8, IL-12, IL-17, IL-6, and MCP, and adhesion molecules such as CCR7, CD40, LFA-1, CD83, and CD86, thus interfering with the migration of inflammatory cells from the blood into airways
This triple-receptor profile makes it a key molecule for studying complex endocrine feedback systems, metabolic signaling networks, and energy-regulation pathways
Animal LD50 studies in mice showed approximately 320 mg per kilogram of body weight, which translates to roughly 22,400 mg for a 154-pound human
Others focused on vascular recovery and broader protective effects throughout the body